Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 7/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237195 | 0.84 | GRIN1 (0.84) | GRIN1GRIN2BTHRBNPC1 | |
| SCHEMBL1388535 | 0.83 | GRIN2B (1.00) | GRIN1GRIN2BTHRBDRD4 | |
| SCHEMBL5208408 | 0.83 | MEN1 (0.56) | GRIN1GRIN2BMEN1KMT2APOLB | |
| SCHEMBL24077252 | 0.81 | MEN1 (0.56) | GRIN1GRIN2BTHRBMEN1KMT2A | |
| SCHEMBL30381107 | 0.81 | MEN1 (0.56) | GRIN1GRIN2BTHRBMEN1KMT2A | |
| SCHEMBL8687575 | 0.81 | DRD4 (0.76) | DRD4LMNAMAPTTSHRNPC1 | |
| SCHEMBL10548102 | 0.79 | THRB (0.64) | GRIN1GRIN2BTHRBMEN1KMT2A | |
| SCHEMBL18297780 | 0.79 | DRD4 (0.57) | DRD4TSHR | |
| SCHEMBL30381638 | 0.79 | MEN1 (0.56) | GRIN1GRIN2BTHRBMEN1KMT2A | |
| SCHEMBL24077253 | 0.79 | MEN1 (0.56) | GRIN1GRIN2BTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565453-A4 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL|BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1565453-A1 | 2- (4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048364-A1 | 2-[(4-BENZYL)-1-PIPERIDINYL)METHYL]BENZIMIDAZOLE-5-OL DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160853-A1 | 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists | GRIN2B, GRIN1, GRIN2A | GRIN1 2/4885GRIN2B 1/4885THRB 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.